Atorvastatin lowers serum calcium levels in lithium-users: results from a randomized controlled trial

Autor: Jocelyn Fotso Soh, Katie Bodenstein, Oriana Hoi Yun Yu, Outi Linnaranta, Suzane Renaud, Artin Mahdanian, Chien-Lin Su, Istvan Mucsi, Benoit Mulsant, Nathan Herrmann, Tarek Rajji, Serge Beaulieu, Harmehr Sekhon, Soham Rej

Publikováno v: BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-7 (2022)

Abstract Background Although lithium is considered the gold-standard treatment for bipolar disorder (BD), it is associated with a variety of major endocrine and metabolic side effects, including parathyroid hormone (PTH) dependent hypercalcemia. Asid

Externí odkaz: https://doaj.org/article/fe458ac4af3a4007814cf0589be6f408

Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial

Autor: Jocelyn Fotso Soh, Susana G. Torres-Platas, Serge Beaulieu, Outi Mantere, Robert Platt, Istvan Mucsi, Sybille Saury, Suzane Renaud, Andrea Levinson, Ana C. Andreazza, Benoit H. Mulsant, Daniel Müller, Ayal Schaffer, Annemiek Dols, Pablo Cervantes, Nancy CP Low, Nathan Herrmann, Birgitte M. Christensen, Francesco Trepiccione, Tarek Rajji, Soham Rej

Publikováno v: BMC Psychiatry, Vol 18, Iss 1, Pp 1-7 (2018)

Abstract Background Lithium is the gold-standard treatment for bipolar disorder, is highly effective in treating major depressive disorder, and has anti-suicidal properties. However, clinicians are increasingly avoiding lithium largely due to fears o

Externí odkaz: https://doaj.org/article/b1bbd3ac2f414c68ab2ac7372bc7c78e

A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users

Autor: Birgitte Mønster Christensen, Luciano D'Apolito, Tarek K. Rajji, Francesco Trepiccione, Daniel J. Müller, Istvan Mucsi, Gabriela Torres-Platas, Nathan Herrmann, Suzane Renaud, Jocelyn Fotso Soh, Pablo Cervantes, Outi Linnaranta, Nancy Low, Andrea Levinson, Benoit H. Mulsant, Sybille Saury, Annemiek Dols, Serge Beaulieu, Ayal Schaffer, Chien Lin Su, Robert W. Platt, Soham Rej

Publikováno v: Fotso Soh, J, Beaulieu, S, Trepiccione, F, Linnaranta, O, Torres-Platas, G, Platt, R W, Renaud, S, Su, C L, Mucsi, I, D’Apolito, L, Mulsant, B H, Levinson, A, Saury, S, Müller, D, Schaffer, A, Dols, A, Low, N, Cervantes, P, Christensen, B M, Herrmann, N, Rajji, T & Rej, S 2021, ' A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users ', Bipolar disorders, vol. 23, no. 1, pp. 66-75 . https://doi.org/10.1111/bdi.12973
Fotso Soh, J, Beaulieu, S, Trepiccione, F, Linnaranta, O, Torres-Platas, G, Platt, R W, Renaud, S, Su, C L, Mucsi, I, D’Apolito, L, Mulsant, B H, Levinson, A, Saury, S, Müller, D, Schaffer, A, Dols, A, Low, N, Cervantes, P, Christensen, B M, Herrmann, N, Rajji, T & Rej, S 2021, ' A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users ', Bipolar Disorders, vol. 23, no. 1, pp. 66-75 . https://doi.org/10.1111/bdi.12973
Bipolar Disorders, 23(1), 66-75. Blackwell Munksgaard

Objective: Lithium remains an important treatment for mood disorders but is associated with kidney disease. Nephrogenic diabetes insipidus (NDI) is associated with up to 3-fold risk of incident chronic kidney disease among lithium users. There are li

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975aa247b1c042c79320f1879cb13fd4
https://pure.au.dk/portal/da/publications/a-doubleblind-randomized-placebocontrolled-pilot-trial-of-atorvastatin-for-nephrogenic-diabetes-insipidus-in-lithium-users(77a7ac8e-c758-4c30-9f11-8644050706ab).html

Current Pharmacotherapies in Older Age Bipolar Disorder

Autor: Jocelyn Fotso Soh, Soham Rej, Ghizlane Moussaoui, Juliana Van Amsterdam, Susana G. Torres-Platas

Publikováno v: Current Treatment Options in Psychiatry. 4:333-340

Background By 2030, more than 50% of patients with bipolar disorder may be aged ≥ 60, with few studies to guide their treatment. In the past few years, a renewed effort has been undertaken to increase the amount of pharmacotherapy research in older

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92819352c7b588f48c8c6b5de3bb537e
https://doi.org/10.1007/s40501-017-0132-y

ATORVASTATIN IN THE TREATMENT OF LITHIUM-INDUCED NEPHROGENIC DIABETES INSIPIDUS: THE PROTOCOL OF A RANDOMIZED CONTROLLED TRIAL

Autor: Annemiek Dols, Istvan Mucsi, Ana Cristina Andreazza, Daniel J. Müller, Jocelyn Fotso Soh, Nathan Herrmann, Birgitte Mønster Christensen, Robert W. Platt, Soham Rej, Susana G. Torres-Platas, Andrea Levinson, Suzane Renaud, Serge Beaulieu, Outi Mantere, Tarek K. Rajji, Ayal Schaffer, Benoit H. Mulsant, Francesco Trepiccione, Nancy Low, Sybille Saury, Pablo Cervantes

Publikováno v: Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, ' Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial ', BMC Psychiatry, vol. 18, no. 1, 227 . https://doi.org/10.1186/s12888-018-1793-9, https://doi.org/10.1186/s12888-018-1793-9
BMC Psychiatry, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Psychiatry, 18(1):227. BioMed Central
Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, ' Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial ', BMC Psychiatry, vol. 18, no. 1, 227 . https://doi.org/10.1186/s12888-018-1793-9
BMC Psychiatry

Introduction Lithium is the gold-standard treatment for bipolar disorder, is highly effective in major depressive disorder, and is being investigated for therapeutic benefits in dementia, stroke, and even cancer. Approximately 350,000 Canadians use l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdbace1eaf53741cbb6a8758d88484c3
https://doi.org/10.1016/j.jagp.2019.01.066